跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CEFAZOLIN IN DEXTROSE INJECTION, USP - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CEFAZOLIN IN DEXTROSE INJECTION, USP
Authorized
STANDARD
CEFAZOLIN IN DEXTROSE INJECTION, USP
baxter corporation
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
29688ca8b4812216
Company
baxter corporation
Type
Standard
Approval Details
Approval Id
29688ca8b4812216
Drug Approval Canada Name
CEFAZOLIN IN DEXTROSE INJECTION, USP
Product Name
CEFAZOLIN IN DEXTROSE INJECTION, USP
Status
Marketed
Status Date
2025-03-06
Original Market Date
2021-01-11
Din
02496313
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
08:12.06.04
Atc Original
J01DB04 CEFAZOLIN
Atc Name
j 01 db 04
Aig Number
0109442009
Company Name
baxter corporation
Company Address
7125 Mississauga Road, Mississauga, Ontario, Canada, L5N 0C2
Active Ingredients
CEFAZOLIN (CEFAZOLIN SODIUM)
20 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
29688ca8b4812216
Type
Standard
Back to Health Canada Approvals